Skip to main content

Market Overview

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year.

The following are catalysts that could dictate the moves of biotech stocks in the unfolding week.


Goldman Sachs 11th Annual Healthcare CEOs Unscripted: A View From The Top is Jan. 3 in New York City.


The FDA is set to announce its verdict on the prior approval supplement, or PAS, submitted by Portola Pharmaceuticals Inc (NASDAQ: PTLA) for its anticoagulant antidote drug Andexxa, which was approved May 3. The application for PAS pertains to a large-scale Generation 2 manufacturing process for Andexxa. The D-day is Dec. 31.

Clinical Trials

Sesen Bio Inc (NASDAQ: SESN) on Jan. 3 will release six-month data from a late-stage study of Vicinium, its investigational candidate for non-muscle invasive bladder cancer.

Pending Q4, Year-End Releases

Some of the releases scheduled for the above period are yet to be reported. Click here for pipeline candidates, the indications for which each is they're being evaluated and the type of data due.

Related Links:

6 Valuable Pipeline Drugs With Upcoming Catalysts

FDA Warms To Considering Legal Cannabis Ingredients In Food


Related Articles (XBI + IBB)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Previews FDA Top Stories Trading Ideas General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at